Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyWPS Meniscal Allograft Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentWPS Health InsurancePolicy PUM 250-0020-1812

    Meniscal Allograft Transplantation Medical Guideline

    Customize your policy alerts

    Sign up for WPS Health Insurance Policy PUM 250-0020-1812 alerts

    Get alerted when Policy PUM 250-0020-1812 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs coverage and medical necessity for meniscal allograft transplantation using a human cadaver meniscus for knee conditions. It applies to providers seeking coverage and requires compliance with the member’s benefit plan, applicable exclusions, prior authorization requirements, and stated clinical criteria.

    Policy Summary
    PayerWPS Health Insurance
    PolicyMeniscal Allograft Transplantation Medical Guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewSep 10, 2026
    Next Review DateN/A
    Key ActionReview the member's benefit plan, contracts, and endorsements for coverage, exclusions, prior authorization, and other benefit requirements.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≤55 yearsMaximum age for covered transplantation
    ≥2 weeksMinimum failed nonsurgical management
    ≥50% absentRequired meniscal absence
    Outerbridge IIMaximum cartilage degeneration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    K-L IIMaximum knee osteoarthritis
    9Experimental or unproven adjunctive treatments

    Coverage Criteria

    Initial meniscal allograft transplantation

    Covered when ALL of the following criteria are met:

    Patient and clinical requirements

    • Eligibility: The individual is skeletally mature, 55 years of age or younger, and ambulatory.Age ≤55 years; skeletal maturity; ambulatory
    • Symptoms and failed treatment: The individual has persistent knee pain that limits function and interferes with normal activities of daily living, and at least two weeks of provider-directed nonsurgical management has failed to improve pain symptoms and function.At least 2 weeks

      Examples include analgesics, anti-inflammatory medication, exercise, or bracing.

    • Joint suitability: The individual is not appropriate for total knee arthroplasty, and the knee has normal stability and alignment or the stability or alignment will be surgically corrected at the time of the allograft procedure.
    • Arthroscopy or imaging findings

      • Meniscal loss after prior surgery or injury results in either an irreparable meniscal tear or prior meniscectomy with absence of at least 50% of the meniscus.At least 50% absent when due to prior meniscectomy

        Either an irreparable tear or qualifying prior meniscectomy is required.

      • Articular cartilage: The surrounding articular cartilage has absent or only minimal degenerative changes.Outerbridge Grade II or less
      • Osteoarthritis: The knee has absent or only minimal osteoarthritic change.Kellgren-Lawrence Scale II or less
      • Growth plates are closed if the individual is less than 18 years old.

    Revision or repeat transplantation

    Revision or repeat transplantation requires Health Plan Medical Director review.

    Revision or repeat procedure: A revision or repeat meniscal allograft transplantation may proceed only after review by the Health Plan's Medical Director.Medical Director review required

    Collagen meniscal implants and tissue-engineered meniscal implants are considered experimental, investigational, and unproven to affect health outcomes. This includes scaffold technology and named systems such as Menaflex®, CMI®, Actifit®, NUsurface®, and silk meniscal scaffold systems.

    Use of a meniscal prosthesis or polyurethane meniscal implant is considered experimental, investigational, and unproven to affect health outcomes.

    Xenotransplantation and xenografts from a different species are considered experimental, investigational, and unproven to affect health outcomes.

    Allograft transplantation for joints other than the knee is considered experimental, investigational, and unproven to affect health outcomes.

    The following devices and adjunctive therapies are considered experimental, investigational, and unproven to affect health outcomes: home use of continuous passive motion devices and related equipment or supplies, the iovera® System, Coolief® Cooled RF, cryotherapy, viscosupplementation or hyaluronic acid injections, stem cell therapy or injections, peripheral nerve ablation, platelet-rich plasma therapy or injections, and genicular nerve injections or genicular nerve radiofrequency ablation.

    Use for a condition or diagnosis listed in the indications but without meeting the stated coverage criteria is considered not medically necessary. Use for a condition or diagnosis not listed in the indications is considered experimental, investigational, and unproven to affect health outcomes.

    Zilretta® (triamcinolone acetonide extended-release injectable suspension) injections are considered not medically necessary.

    Clinical Thresholds and Coding Details

    Eligibility thresholds
    Maximum covered age55 years or younger
    Maturity requirementThe individual must be skeletally mature.
    Ambulation requirementThe individual must be ambulatory.
    Conservative management threshold
    Minimum durationAt least two weeks
    Required outcomeProvider-directed nonsurgical management must have failed to improve pain symptoms and function.
    ExamplesAnalgesics, anti-inflammatory medication, exercise, or bracing.

    Provider Requirements and Action Items

    Prior Authorization

    Verify Plan-Specific Requirements

    Verify plan-specific requirements before providing services. Coverage may vary by plan; review the member’s benefit plan, contracts, endorsements, exclusions, prior authorization requirements, and other benefit requirements.

    Prior Authorization

    Medical Director Review Required

    Revision or repeat meniscal allograft transplantation requires review by the Health Plan Medical Director. Obtain this review before proceeding with a repeat or revision procedure.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: billing_rule

    Clinical Background

    The meniscus is crescent-shaped cartilage in the knee that cushions the joint, disperses weight, and reduces friction. Each knee has a medial and lateral meniscus. Meniscal allograft transplantation removes a damaged meniscus and replaces it with a donated meniscus from a deceased person. This guideline addresses transplantation using a human cadaver meniscus for selected skeletally mature, ambulatory individuals with persistent function-limiting knee pain and limited degenerative joint disease.

    Definitions

    Meniscus
    StructureA crescent-shaped piece of cartilage that provides a cushion between the bones of the knee joint.
    Knee anatomyEach knee has an inner medial meniscus and an outer lateral meniscus.
    FunctionThe menisci act as shock absorbers by dispersing weight and reducing friction.
    Meniscal allograft transplantation
    ProcedureThe damaged meniscus is removed and a new meniscus is placed in the knee.
    Tissue sourceThe replacement meniscus is donated by a deceased person.
    Procedure name
    Policy Summary
    PayerWPS Health Insurance
    PolicyMeniscal Allograft Transplantation Medical Guideline
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewSep 10, 2026
    Next Review DateN/A
    Key ActionReview the member's benefit plan, contracts, and endorsements for coverage, exclusions, prior authorization, and other benefit requirements.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Coding DetailsProvider Requirements and Action ItemsClinical BackgroundDefinitions
    Closed growth plates

    This confirms skeletal maturity for individuals younger than 18.

    Meniscal loss threshold
    Required meniscal absenceAt least 50% of the meniscus must be absent after prior meniscectomy.
    Qualifying meniscal lossMeniscal loss must result from prior surgery or injury.
    Alternative findingAn irreparable meniscal tear also qualifies as a meniscal-loss finding.
    Articular cartilage threshold
    Maximum degeneration gradeOuterbridge Grade II or less.
    Cartilage statusSurrounding articular cartilage must have absent or only minimal degenerative changes.
    Confirmation methodThe cartilage finding must be confirmed by arthroscopy or imaging studies.
    Knee osteoarthritis threshold
    Maximum osteoarthritis severityKellgren-Lawrence Scale II or less.
    Osteoarthritic statusThe knee must have absent or only minimal osteoarthritic change.
    Confirmation methodThe osteoarthritis finding must be confirmed by arthroscopy or imaging studies.
    Denial Risk

    Unlisted Diagnosis or Condition

    Use for a condition or diagnosis other than one listed in the Indications of Coverage is considered experimental, investigational, and unproven to affect health outcomes.

    Denial Risk

    Indications Criteria Not Met

    Use for a listed condition or diagnosis when the coverage criteria are not met is considered not medically necessary.

    Denial Risk

    Excluded Implants and Adjunctive Therapies

    The following implants, procedures, devices, and adjunctive treatments are considered experimental, investigational, and unproven to affect health outcomes.

    • Collagen meniscal implants or tissue-engineered meniscal implants, including scaffold technology, Menaflex®, CMI®, Actifit®, NUsurface®, and silk meniscal scaffold systems.
    • Meniscal prostheses, polyurethane meniscal implants, xenotransplantation or xenografts, and allograft transplantation for joints other than the knee.
    • Home-use continuous passive motion devices and related equipment or supplies; iovera® System; Coolief® Cooled RF; and cryotherapy.
    • Viscosupplementation or hyaluronic acid injections; stem cell therapy or injections; peripheral nerve ablation; platelet-rich plasma therapy or injections; and genicular nerve injections or genicular nerve radiofrequency ablation.
    Denial Risk

    Zilretta Injections

    Zilretta (triamcinolone acetonide extended-release injectable suspension) injections are considered not medically necessary.

    Meniscal allograft transplantation (MAT).